1 – 6 of 6
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2019
-
Mark
All-oral ixazomib, cyclophosphamide, and dexamethasone for transplant-ineligible patients with newly diagnosed multiple myeloma
(
- Contribution to journal › Article
- 2018
-
Mark
Lenalidomide versus lenalidomide + dexamethasone prolonged treatment after second-line lenalidomide + dexamethasone induction in multiple myeloma
(
- Contribution to journal › Article
- 2016
-
Mark
Melphalan, prednisone, and lenalidomide versus melphalan, prednisone, and thalidomide in untreated multiple myeloma.
(
- Contribution to journal › Article
- 2013
-
Mark
Bortezomib consolidation after autologous stem cell transplantation in multiple myeloma: a Nordic Myeloma Study Group randomized phase 3 trial
(
- Contribution to journal › Article
- 2010
-
Mark
Multiparametric Flow Cytometry Profiling of Neoplastic Plasma Cells in Multiple Myeloma
(
- Contribution to journal › Article
- 2009
-
Mark
Improved Response Rate with Bortezomib Consolidation After High Dose Melphalan: First Results of a Nordic Myeloma Study Group Randomized Phase III Trial
(
- Contribution to journal › Published meeting abstract